2025년 신임 등기이사 Ph.D. Stuart Petlz의 Biography 

Scientific and Platform Innovation A seminal figure in RNA biology, Dr. Peltz spearheaded the creation of PTC’s proprietary platforms in RNA modulation, enabling the discovery and development of multiple first- and best-in-class medicines. His academic work, which includes a professorship at Robert Wood Johnson Medical School and over 100 scientific publications, provides the foundation for the company's scientific rigor.

A Legacy of Transformative Therapies Dr. Peltz's leadership has directly resulted in a portfolio of groundbreaking medicines that have changed the standard of care for thousands of patients worldwide This includes: Evrysdi (risdiplam): Spearheaded the discovery and development of the first oral therapy for spinal muscular atrophy (SMA), in partnership with Roche. Evrysdi is now a global blockbuster that generated over $1.2 billion in 2022, fundamentally transforming the treatment landscape for SMA; Translarna (ataluren): Delivered the first-ever approved therapy for nonsense mutation Duchenne muscular dystrophy (nmDMD) in Europe, creating a new therapeutic path for patients with this devastating genetic disorder; Upstaza (eladocagene exuparvovec): Achieved European approval for this first-in-class gene therapy for AADC deficiency, a landmark achievement as one of the first gene therapies delivered directly to the brain/ Emflaza (deflazacort): Executed the strategic acquisition and successful U.S. launch of the only corticosteroid approved for all DMD patients, establishing a new standard of care and significantly reducing the burden on families; Sephience (Sepiapterin): recently approved in the EU and US. A new treatment that will benefit the vast majority patients suffering from PKU.

Groundbreaking Pipeline Programs: Drove a robust discovery and clinical pipeline. For example, PTC518 to treat Huntington’s Disease was identified using our pioneering an innovative oral splicing platform to lower the protein that is the underlying cause of the disease. PTC518 was partnered with Novartis for >$1B in upfront payment with substantial royalties and milestones. Strategic Global Commercialization: Secured exclusive rights to commercialize Tegsedi and Waylivra in Latin America, demonstrating a commitment to expanding global access for innovative RNA-targeted medicines.

Industry Recognition and Leadership Dr. Peltz is one of the rare biotech CEOs to be elected a Fellow of the American Association for the Advancement of Science (AAAS) for his distinguished contributions to genetics and RNA biochemistry—a distinction that places him in the highest echelon of scientist-leaders. His visionary leadership has been recognized with a myriad of prestigious industry’s honors, including the Dr. Sol J. Barer Award for Vision, Innovation and Leadership, the Legend of Technology Award, induction into the NJ High Tech Hall of Fame & the EURORDIS Black Pearl Company Award for Innovation.

Biotechnology's Foundational Leaders Dr. Peltz is widely regarded among the elite tier of founder-CEOs who have built enduring, science-driven companies from the ground up. His legacy, akin to that of the top CEOs, is defined by the rare ability to translate profound scientific and business expertise into multiple, life-changing therapies and global commercial success.